Beth C. Seidenberg serves as Director of Latigo Biotherapeutics, Inc. (LTGO). Seidenberg has also held reporting roles at Sagimet Biosciences Inc. (SGMT) and Kyverna Therapeutics, Inc. (KYTX). Seidenberg has reported 9 insider filings with the SEC since 2024. The most recent filing was in August 2026.
Every role Beth C. Seidenberg has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Latigo Biotherapeutics, Inc. (LTGO)1 filingSagimet Biosciences Inc. (SGMT)1 filingUpdated Aug 30, 2026
Beth C. Seidenberg is Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). 9 SEC Form 4 filings on record going back to 2024, most recently on 11 August 2026. Most recent open-market trade: sold $10K of VERA on 30 October 2024. Lifetime open-market sales: $720K.
Every recent SEC Form 4 transaction Beth C. Seidenberg has reported, most recent first.
InsiderAlpha's records for Beth C. Seidenberg go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 2 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Beth C. Seidenberg files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Beth C. Seidenberg is a corporate insider, tracked as Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases and 2 open-market sales ($720K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$LTGO Latigo Biotherapeutics, Inc.1.48M shares @ --